These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 28688781

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A, Prymula R, Miranda Valdivieso M, Otero Reigada MDC, Merino Arribas JM, Brzostek J, Szenborn L, Ruzkova R, Horn MR, Jackowska T, Centeno-Malfaz F, Traskine M, Dobbelaere K, Borys D.
    Vaccine; 2019 Jan 03; 37(1):176-186. PubMed ID: 30054160
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    AIDS; 2015 Jul 17; 29(11):1345-54. PubMed ID: 25888646
    [Abstract] [Full Text] [Related]

  • 4. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M, Abboud MR, Fiquet A, Inati A, Lebensburger JD, Kaddah N, Mokhtar G, Piga A, Halasa N, Inusa B, Rees DC, Heath PT, Telfer P, Driscoll C, Al Hajjar S, Tozzi A, Jiang Q, Emini EA, Gruber WC, Gurtman A, Scott DA.
    Pediatr Blood Cancer; 2015 Aug 17; 62(8):1427-36. PubMed ID: 25810327
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
    Wysocki J, Brzostek J, Szymański H, Tetiurka B, Toporowska-Kowalska E, Wasowska-Królikowska K, Sarkozy DA, Giardina PC, Gruber WC, Emini EA, Scott DA.
    Vaccine; 2015 Mar 30; 33(14):1719-25. PubMed ID: 25698485
    [Abstract] [Full Text] [Related]

  • 6. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.
    Silfverdal SA, Flodmark CE, Rombo L, Tansey SP, Sidhu M, Trammel J, Emini EA, Gruber WC, Scott DA, Gurtman A, 3012 study group.
    Vaccine; 2013 Feb 18; 31(9):1284-92. PubMed ID: 23306363
    [Abstract] [Full Text] [Related]

  • 7. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
    Quinet B, Laudat F, Gurtman A, Patterson S, Sidhu M, Gruber WC, Scott DA.
    Pediatr Infect Dis J; 2014 Oct 18; 33(10):1065-76. PubMed ID: 25093973
    [Abstract] [Full Text] [Related]

  • 8. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
    Platt HL, Greenberg D, Tapiero B, Clifford RA, Klein NP, Hurley DC, Shekar T, Li J, Hurtado K, Su SC, Nolan KM, Acosta CJ, McFetridge RD, Bickham K, Musey LK, V114-008 Study Group.
    Pediatr Infect Dis J; 2020 Aug 18; 39(8):763-770. PubMed ID: 32639460
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients.
    Hung TY, Kotecha RS, Blyth CC, Steed SK, Thornton RB, Ryan AL, Cole CH, Richmond PC.
    Cancer; 2017 Nov 01; 123(21):4215-4223. PubMed ID: 28696530
    [Abstract] [Full Text] [Related]

  • 10. No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
    Licciardi PV, Toh ZQ, Clutterbuck EA, Balloch A, Marimla RA, Tikkanen L, Lamb KE, Bright KJ, Rabuatoka U, Tikoduadua L, Boelsen LK, Dunne EM, Satzke C, Cheung YB, Pollard AJ, Russell FM, Mulholland EK.
    J Allergy Clin Immunol; 2016 Jun 01; 137(6):1772-1779.e11. PubMed ID: 26825000
    [Abstract] [Full Text] [Related]

  • 11. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC).
    MMWR Recomm Rep; 2010 Dec 10; 59(RR-11):1-18. PubMed ID: 21150868
    [Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT, Stacey HL, MacNair JE, Li J, Hartzel JS, Sterling TM, Benner P, Tamms GM, Musey LK.
    Hum Vaccin Immunother; 2019 Dec 10; 15(3):540-548. PubMed ID: 30427749
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
    Temple B, Toan NT, Dai VTT, Bright K, Licciardi PV, Marimla RA, Nguyen CD, Uyen DY, Balloch A, Huu TN, Mulholland EK.
    Lancet Infect Dis; 2019 May 10; 19(5):497-509. PubMed ID: 30975525
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA, PCV13 Infant Study Group.
    Pediatrics; 2010 May 10; 125(5):866-75. PubMed ID: 20435707
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
    Madhi SA, Mutsaerts EA, Izu A, Boyce W, Bhikha S, Ikulinda BT, Jose L, Koen A, Nana AJ, Moultrie A, Roalfe L, Hunt A, Goldblatt D, Cutland CL, Dorfman JR.
    Lancet Infect Dis; 2020 Dec 10; 20(12):1426-1436. PubMed ID: 32857992
    [Abstract] [Full Text] [Related]

  • 16. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.
    Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ, Snape MD, Martinón-Torres F, Gruber WC, Patterson S, Thompson A, Gurtman A, Paradiso P, Scott DA.
    Vaccine; 2013 Oct 01; 31(42):4765-74. PubMed ID: 23965217
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China.
    Zhu F, Hu Y, Li J, Ye Q, Young MM, Zhou X, Chen Z, Yan B, Liang JZ, Gruber WC, Giardina PC, Scott DA.
    Pediatr Infect Dis J; 2016 Sep 01; 35(9):999-1010. PubMed ID: 27254028
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
    Adigweme I, Futa A, Saidy-Jah E, Edem B, Akpalu E, Dibbasey T, Sethna V, Dhere R, Kampmann B, Bengt C, Sirr J, Hosken N, Goldblatt D, Antony K, Alderson MR, Lamola S, Clarke E.
    Lancet Infect Dis; 2023 May 01; 23(5):609-620. PubMed ID: 36638819
    [Abstract] [Full Text] [Related]

  • 19. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
    Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA.
    Clin Infect Dis; 2013 Oct 01; 57(7):952-62. PubMed ID: 23804191
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
    Stacey HL, Rosen J, Peterson JT, Williams-Diaz A, Gakhar V, Sterling TM, Acosta CJ, Nolan KM, Li J, Pedley A, Benner P, Abeygunawardana C, Kosinski M, Smith WJ, Pujar H, Musey LK.
    Hum Vaccin Immunother; 2019 Oct 01; 15(3):530-539. PubMed ID: 30648919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.